Gonzalez-Crussi F, Hsueh W
Am J Pathol. 1983 Jul;112(1):127-35.
This report deals with the experimental production of ischemic bowel necrosis in rats by the administration of combined bacterial lipopolysaccharide (LPS) and platelet-activating factor (PAF). Neither LPS alone, nor PAF at a low dose, caused ischemic intestinal necrosis when administered intraaortically. With these two compounds in combination, necrotizing lesions of the gastrointestinal tract developed consistently. The lesions showed marked morphologic similarity to human necrotizing enterocolitis (NEC). There were no thrombi in mesenteric arteries or necrotic lesions in other organs to which these bioactive compounds were delivered. These findings suggest a possible synergistic involvement of PAF and LPS in the pathogenesis of NEC and other forms of ischemic bowel necrosis. The authors further suggest that the pathogenesis of experimental NEC in rats is independent of platelet aggregation.
本报告探讨了通过联合给予细菌脂多糖(LPS)和血小板活化因子(PAF)在大鼠中实验性诱导缺血性肠坏死。单独给予LPS或低剂量的PAF经主动脉内给药时,均未引起缺血性肠坏死。当这两种化合物联合使用时,胃肠道的坏死性病变持续出现。这些病变在形态学上与人类坏死性小肠结肠炎(NEC)具有显著相似性。在这些生物活性化合物所输送至的肠系膜动脉中没有血栓形成,其他器官也没有坏死性病变。这些发现提示PAF和LPS可能在NEC及其他形式的缺血性肠坏死的发病机制中存在协同作用。作者进一步表明,大鼠实验性NEC的发病机制与血小板聚集无关。